Mercks phase 3 KEYNOTE-671 trial of Keytruda meets primary endpoint of EFS in patients with resectable stage II, IIIA or IIIB NSCLC

Merck, known as MSD outside of the United States and Canada, announced that the phase 3 KEYNOTE-671 trial investigating Keytruda, Merck